BTG2016 Scientific Agenda: Session Day 1
SATURDAY, FEBRUARY 27, 2016
CLICK HERE FOR CORPORATE DAY:FEB 26
CLICK HERE FOR DAY 2: FEB 28
REGISTRATION DESK: 6:30 AM - 4:00 PM
PLENARY SESSION: 8:00 AM - 5:00 PM
INAUGURATION SESSION
8:00 AM-8:30 AM
Opening Note
Morton Coleman, MD (Cornell University, New York, USA)
Welcome Note
Juan Li, MD (Sun Yat-Sen University, Guangzhou, China)
Robert Orlowski, MD, PhD (MD Anderson Cancer Center, Houston, USA )
APHCON Update
Xiaojun Huang, MD, PhD (Peking University, Beijing, China)
MULTIPLE MYELOMA SESSION
8:30 AM-10:00 AM Multiple Myeloma- I
Moderators：Kaiyan Liu & Wenming Chen
8:30 AM
The future of antibody therapies and drug conjugates in multiple myeloma
Robert Orlowski, MD, PhD (MD Anderson Cancer Center, Houston, USA )
8:50 AM
The optimal induction therapy for newly diagnosed transplant eligible myeloma?
James Chim, MD, PhD (University of Hong Kong, Pok Fu Lam, Hong Kong)
9:10 AM
Is ‘Induction-ASCT-Maintenance’ the therapy of choice for all patients with newly diagnosed myeloma?
Juan Li, MD (Sun Yat-Sen University, Guangzhou, China)
9:20 AM
Debate Session: Should we treat smoldering myeloma?
Yes: Jin Lu, MD (Peking University, Beijing, China)
No: Chepsy Philip, MD (CMC Ludhiana, Chandigarh, India)
9:40 AM
APHCON YOUTH CONGRESS ANNOUNCEMENT
Moderators: XJ Huang, Surapol Issaragrisil & Simrit Parmar
10:00-10:30 AM COFFEE BREAK
10:30 AM-12:00 PM Multiple Myeloma - II
Moderators: Daobin Zhou & William Hwang
10:30 AM
MRD Assessment and it application for multiple myeloma
Jian Hou, MD (Shanghai Changzheng Hospital, Shanghai, China)
10:45 AM Debate Session: What is optimal maintenance therapy duration for a newly diagnosed multiple myeloma patients completing induction, ASCT and consolidation?
Maintenance for 2 years only: Nuchanan Areethamsirikul, MD (Siriraj Hospital, Bangkok, Thailand)
Continuous maintenance therapy: Govind Babu, MD (Kidwai Memorial Institute, Bangalore,India)
11:15 AM
Immunotherapy in Multiple Myeloma
Robert Orlowski, MD, PhD (MD Anderson Cancer Center, Houston, USA )
11:45 AM: Q and A
12:00 PM-2:00 PM Lunch Session
12:00 - 1:00 PM CELGENE: MULTIPLE MYELOMA
Moderator: Xiaojun Huang, MD, PhD and Kaiyan Liu, MD, PhD
- MM ASH 2015 highlights (20 min): Wenming CHEN, MD Beijing Chaoyang hospital
- Newly diagnosed multiple myeloma treatment updates (20 min): Jin LU, MD Peking University People Hospital
- Relapsed/Refractory multiple myeloma treatment updates (20 min): Jian HOU, MD, PhD Shanghai Changzheng hospital
1:00 - 2:00 PM SANOFI: GVHD
Moderator: Kaiyan Liu, MD, PhD (Peking University, Beijing, China)
Speaker: He Huang, MD, PhD (Zhejiang University School of Medicine, Hangzhou, China)
LYMPHOMA SESSION
2:00 PM – 3:00 PM Low Grade Lymphoma
Moderators：Yongping Song & Daryl Tan
2:00 PM
Debate Session: How should a 63 year old male with advanced stage, intermediate risk MIPI mantle cell be treated outside of a clinical trial?
Chemoimmunotherapy with AutoSCT: William Hwang, MD (National University Singapore, Singapore)
Chemotherapy-based therapy without transplant: Piyanuch Kongtim, MD (Siriraj Hospital, Bangkok, Thailand)
2:20 PM
Debate Session: A 60 year old man with stage I (excised) follicular lymphoma, now NED. How should he be treated?
Observation: Pankaj Malhotra, MD (PGIMER, Chandigarh, India)
Radiation therapy, with or without systemic treatment: Adolfo de la Fuenta, MD (MD Anderson Cancer Center, Madrid, Spain)
2:40 PM
Debate: A 48-year-old woman is diagnosed with mildly symptomatic, low tumor burden, stage IV follicular lymphoma, low risk FLIPI score and desires treatment. What is your recommendation?
R-CHOP or B-R: Weili Zhao, MD (Shanghai Ruijin Hospital, Shanghai, China)
Single agent rituximab or a combination “biologic doublet” therapy: Swami Iyer, MD (Houston Methodist Cancer Center, Houston, USA)
3:00 PM – 3:45 PM B Cell Lymphoma
Moderators: Junmin Li & Nuchanan Areethamsirikul
3:00 PM
Double hit lymphoma. What is it and how should we treat it?
Morton Coleman, MD (Cornell University, New York, USA)
3:10 PM
Debate: Should we treat patients with DLBCL differently today based on cell of origin (Germinal Center/Non-Germinal Center)?
Yes: Daryl Tan, MD (Raffles Hospital, Singapore)
No: Frederick Hagemeister, MD (MD Anderson Cancer Center, Houston, USA)
3:30 PM
Upfront autologous transplant in high risk DLBCL. The current guidelines and recommendations
David Ritchie, MD, PhD (Royal Melbourne Hospital, Melbourne, Australia)
3:50 PM-4:10 PM Coffee Break
4:10 PM – 5:00 PM T Cell Lymphoma
Moderators: Qifa Liu & Piyanuch Kongtim
4:10 PM
Current challenges in diagnosis and management of extranodal NK/T cell Lymphoma nasal type
Tong Yu Lin, MD (Sun Yat-Sen University, Guangzhou, China)
4:20 PM
Recent treatment for NK/T cell lymphoma: Chinese experience
Huiqiang Huang, MD (Sun Yat-Sen University Cancer Center, Guangzhou, China)
4:30 PM
Targeted Therapy for PTCL
YL Kwong, MD, PhD (University of Hong Kong)
4:45 PM
Allogeneic transplant for Lymphoma
Dharma Choudhary, MD (BLK Hospital, New Delhi)
5:00 PM ADJOURN
5:30 PM APHCON President Reception
CLICK HERE FOR DAY 2: FEB 28
REGISTRATION DESK: 6:30 AM - 4:00 PM
PLENARY SESSION: 8:00 AM - 5:00 PM
INAUGURATION SESSION
8:00 AM-8:30 AM
Opening Note
Morton Coleman, MD (Cornell University, New York, USA)
Welcome Note
Juan Li, MD (Sun Yat-Sen University, Guangzhou, China)
Robert Orlowski, MD, PhD (MD Anderson Cancer Center, Houston, USA )
APHCON Update
Xiaojun Huang, MD, PhD (Peking University, Beijing, China)
MULTIPLE MYELOMA SESSION
8:30 AM-10:00 AM Multiple Myeloma- I
Moderators：Kaiyan Liu & Wenming Chen
8:30 AM
The future of antibody therapies and drug conjugates in multiple myeloma
Robert Orlowski, MD, PhD (MD Anderson Cancer Center, Houston, USA )
8:50 AM
The optimal induction therapy for newly diagnosed transplant eligible myeloma?
James Chim, MD, PhD (University of Hong Kong, Pok Fu Lam, Hong Kong)
9:10 AM
Is ‘Induction-ASCT-Maintenance’ the therapy of choice for all patients with newly diagnosed myeloma?
Juan Li, MD (Sun Yat-Sen University, Guangzhou, China)
9:20 AM
Debate Session: Should we treat smoldering myeloma?
Yes: Jin Lu, MD (Peking University, Beijing, China)
No: Chepsy Philip, MD (CMC Ludhiana, Chandigarh, India)
9:40 AM
APHCON YOUTH CONGRESS ANNOUNCEMENT
Moderators: XJ Huang, Surapol Issaragrisil & Simrit Parmar
10:00-10:30 AM COFFEE BREAK
10:30 AM-12:00 PM Multiple Myeloma - II
Moderators: Daobin Zhou & William Hwang
10:30 AM
MRD Assessment and it application for multiple myeloma
Jian Hou, MD (Shanghai Changzheng Hospital, Shanghai, China)
10:45 AM Debate Session: What is optimal maintenance therapy duration for a newly diagnosed multiple myeloma patients completing induction, ASCT and consolidation?
Maintenance for 2 years only: Nuchanan Areethamsirikul, MD (Siriraj Hospital, Bangkok, Thailand)
Continuous maintenance therapy: Govind Babu, MD (Kidwai Memorial Institute, Bangalore,India)
11:15 AM
Immunotherapy in Multiple Myeloma
Robert Orlowski, MD, PhD (MD Anderson Cancer Center, Houston, USA )
11:45 AM: Q and A
12:00 PM-2:00 PM Lunch Session
12:00 - 1:00 PM CELGENE: MULTIPLE MYELOMA
Moderator: Xiaojun Huang, MD, PhD and Kaiyan Liu, MD, PhD
- MM ASH 2015 highlights (20 min): Wenming CHEN, MD Beijing Chaoyang hospital
- Newly diagnosed multiple myeloma treatment updates (20 min): Jin LU, MD Peking University People Hospital
- Relapsed/Refractory multiple myeloma treatment updates (20 min): Jian HOU, MD, PhD Shanghai Changzheng hospital
1:00 - 2:00 PM SANOFI: GVHD
Moderator: Kaiyan Liu, MD, PhD (Peking University, Beijing, China)
Speaker: He Huang, MD, PhD (Zhejiang University School of Medicine, Hangzhou, China)
LYMPHOMA SESSION
2:00 PM – 3:00 PM Low Grade Lymphoma
Moderators：Yongping Song & Daryl Tan
2:00 PM
Debate Session: How should a 63 year old male with advanced stage, intermediate risk MIPI mantle cell be treated outside of a clinical trial?
Chemoimmunotherapy with AutoSCT: William Hwang, MD (National University Singapore, Singapore)
Chemotherapy-based therapy without transplant: Piyanuch Kongtim, MD (Siriraj Hospital, Bangkok, Thailand)
2:20 PM
Debate Session: A 60 year old man with stage I (excised) follicular lymphoma, now NED. How should he be treated?
Observation: Pankaj Malhotra, MD (PGIMER, Chandigarh, India)
Radiation therapy, with or without systemic treatment: Adolfo de la Fuenta, MD (MD Anderson Cancer Center, Madrid, Spain)
2:40 PM
Debate: A 48-year-old woman is diagnosed with mildly symptomatic, low tumor burden, stage IV follicular lymphoma, low risk FLIPI score and desires treatment. What is your recommendation?
R-CHOP or B-R: Weili Zhao, MD (Shanghai Ruijin Hospital, Shanghai, China)
Single agent rituximab or a combination “biologic doublet” therapy: Swami Iyer, MD (Houston Methodist Cancer Center, Houston, USA)
3:00 PM – 3:45 PM B Cell Lymphoma
Moderators: Junmin Li & Nuchanan Areethamsirikul
3:00 PM
Double hit lymphoma. What is it and how should we treat it?
Morton Coleman, MD (Cornell University, New York, USA)
3:10 PM
Debate: Should we treat patients with DLBCL differently today based on cell of origin (Germinal Center/Non-Germinal Center)?
Yes: Daryl Tan, MD (Raffles Hospital, Singapore)
No: Frederick Hagemeister, MD (MD Anderson Cancer Center, Houston, USA)
3:30 PM
Upfront autologous transplant in high risk DLBCL. The current guidelines and recommendations
David Ritchie, MD, PhD (Royal Melbourne Hospital, Melbourne, Australia)
3:50 PM-4:10 PM Coffee Break
4:10 PM – 5:00 PM T Cell Lymphoma
Moderators: Qifa Liu & Piyanuch Kongtim
4:10 PM
Current challenges in diagnosis and management of extranodal NK/T cell Lymphoma nasal type
Tong Yu Lin, MD (Sun Yat-Sen University, Guangzhou, China)
4:20 PM
Recent treatment for NK/T cell lymphoma: Chinese experience
Huiqiang Huang, MD (Sun Yat-Sen University Cancer Center, Guangzhou, China)
4:30 PM
Targeted Therapy for PTCL
YL Kwong, MD, PhD (University of Hong Kong)
4:45 PM
Allogeneic transplant for Lymphoma
Dharma Choudhary, MD (BLK Hospital, New Delhi)
5:00 PM ADJOURN
5:30 PM APHCON President Reception